

Investigating the Role of Myeloperoxidase and Angiotensin-like Protein 6 in Obesity and Diabetes

Mohammad G. Qaddoumi ^{1,2}, Muath Alanbaei ³, Maha M. Hammad ¹, Irina Al-Khairi ¹, Preethi Cherian ¹, Arshad Channanath⁴, Thangavel Alphonse Thanaraj⁴, Fahd Al-Mulla ⁴, Mohamed Abu-Farha ^{1*}, and Jehad Abubaker ^{1*}

- ¹ Biochemistry and Molecular Biology, Dasman Diabetes Institute, Kuwait City, Kuwait.
- ² Pharmacology and Therapeutics Department, Faculty of Pharmacy, Kuwait University, Kuwait City, Kuwait.
- ³ Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait.
- ⁴ Functional Genomic Unit, Dasman Diabetes Institute, 15462 Kuwait City, Kuwait;

* Correspondence: jehad.abubakr@dasmaninstitute.org; mohamed.abufarha@dasmaninstitute.org;
Tel.: +965 2224-2999

Supplementary Table S1: Association between circulating ANGPTL6 or MPO levels and the outcomes of diabetes and obesity using multivariate logistic regression

	T2D AOR [95%CI]	p-value	Obesity AOR [95%CI]	p-value
ANGPTL6 (ng/mL)	1.04 [1.01-1.08]	0.005	1.03[1.01-1.06]	0.023
MPO (ng/mL)	0.99 [0.98-1.01]	0.694	1.01[0.99-1.02]	0.065

ANGPTL6: Angiotensin-like protein 6; AOR: Adjusted odds ratio (adjusted for age and gender);
MPO: Myeloperoxidase